Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin has signed a co-promotion agreement with Santen Pharmaceutical for Eylea (aflibercept) injection in Japan.
Eylea is approved for sale in the US and Australia for the treatment of neovascular age-related macular degeneration (wet AMD).
Under the agreement, Bayer owns the exclusive marketing rights outside the US, where the companies will share equally the profits from any future sales of Eylea, except for Japan where Regeneron will receive a royalty on net sales.
Bayer Yakuhin President & CEO Sebastian Guth said, "We expect that the combined resources of the two companies will allow EYLEA to achieve a broader and faster reach into the Japanese ophthalmology community and potentially benefit a greater number of patients."
Currently, Eylea is being studied in Phase 3 clinical trials for the treatment of diabetic macular edema (DME), myopic choroidal neovascularization (mCNV), and branch retinal vein occlusion (BRVO).
